Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Tema GLP-1, Obesity & Cardiometabolic ETF
(NQ:
HRTS
)
29.61
+0.08 (+0.27%)
Streaming Delayed Price
Updated: 11:41 AM EST, Dec 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tema GLP-1, Obesity & Cardiometabolic ETF
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
December 20, 2024
Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market overreacted.
Via
Benzinga
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
September 25, 2024
Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on company's bottom line.
Via
Benzinga
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
July 18, 2024
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.
Via
Benzinga
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
July 07, 2024
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs.
Via
Benzinga
Topics
ETFs
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
July 05, 2024
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.
Via
Investor's Business Daily
Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
May 29, 2024
The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to...
Via
Benzinga
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
April 17, 2024
The results also pressured ResMed, a maker of CPAPs. CPAPs are the common treatment for sleep apnea.
Via
Investor's Business Daily
Healthcare ETFs For The Weight-Loss Drug Boom And Beyond
April 08, 2024
Two dominant investing themes over the past year have been AI and weight-loss drugs.
Via
Talk Markets
Topics
Artificial Intelligence
ETFs
Exposures
Artificial Intelligence
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
February 23, 2024
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.
Via
Investor's Business Daily
Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only Growing
January 29, 2024
David Song, PM of the Cardiovascular and Metabolic ETF (NASDAQ: HRTS) for Tema ETFs, was recently interviewed by Benzinga.
Via
Benzinga
Topics
ETFs
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
December 04, 2023
Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic
Via
Benzinga
EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads
December 01, 2023
Tema ETFs is redefining thematic investing, focusing on long-term structural trends & precision in security selection rather than chasing short-term fads.
Via
Benzinga
Topics
ETFs
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.